RTP Mobile Logo
Oncology Grand Rounds: Part 2 — Gastrointestinal Cancers
Released July 2018

Video proceedings from the second in a series of 6 integrated symposia held at the 2018 ONS Annual Congress. Featuring perspectives from Dr Tanios Bekaii-Saab, Mr Michael Casey, Dr John L Marshall and Ms Jessica Mitchell. (Video Program)

CE Disclosures and Faculty Information

  • TARGET AUDIENCE
    This activity has been designed to meet the educational needs of oncology nurses, nurse practitioners and clinical nurse specialists involved in the treatment of gastrointestinal (GI) cancers.

    OVERVIEW OF ACTIVITY
    Given the prevalent nature of the disease, extensive resources are allocated to colorectal cancer (CRC) research and education. Interestingly, however, although individually less frequently encountered, the collection of other, “non-CRC” GI cancers accounts for more per annum deaths than those attributed to tumors of the colon and rectum combined. As such, educational opportunities relevant to the clinical management of CRC and prevalent non-CRC GI tumors, including gastric, pancreatic and hepatocellular cancer, are essential to the delivery of comprehensive care.

    Although medical oncologists have been routinely responsible for counseling patients with regard to therapeutic decision-making, oncology nurses play an integral role in the successful delivery of systemic anticancer therapy and the preservation of patient physical and psychosocial well-being. These video proceedings from the second part of a 6-part integrated CNE curriculum originally held at the 2018 ONS Annual Congress feature discussions with leading GI cancer investigators and their nursing counterparts regarding actual patient cases and recent clinical research findings affecting the optimal therapeutic and supportive care for each patient scenario.

    PURPOSE STATEMENT
    By providing information on the latest research developments in the context of expert perspectives, this CNE activity will assist oncology nurses, nurse practitioners and clinical nurse specialists with the formulation of state-of-the-art clinical management strategies to facilitate optimal care of patients with GI cancers.

    LEARNING OBJECTIVES

    • Apply available research data to the therapeutic and supportive care of patients with pancreatic cancer, gastric/gastroesophageal junction (GEJ) cancer, CRC and hepatocellular carcinoma (HCC).
    • Consider age, performance status and other clinical and logistical factors in the selection of systemic therapy for patients with localized, locally advanced or metastatic pancreatic cancer.
    • Use HER2 status, PD-L1 combined positive score, clinical factors and patient preferences to optimize systemic therapy for locally advanced or metastatic gastric/GEJ cancer.
    • Recognize the importance of biomarker analysis for patients diagnosed with CRC or gastric/GEJ cancer, and use this information to counsel these individuals regarding the selection of evidence-based systemic treatment options.
    • Describe the clinical indications, benefits and toxicities associated with the use of existing and recently approved systemic therapies in the management of metastatic CRC.
    • Communicate the benefits and risks of approved and emerging systemic interventions to patients with locally advanced or metastatic HCC.
    • Appraise the rationale for and clinical data with commercially available and developmental immune checkpoint inhibitors in the treatment of GI cancers.

    ACCREDITATION STATEMENT
    Research To Practice (RTP) is accredited as a provider of continuing nursing education by the American Nurses Credentialing Center’s (ANCC) Commission on Accreditation.

    CREDIT DESIGNATION STATEMENT
    This educational activity for 1.7 contact hours is provided by RTP during the period of July 2018 through July 2019.

    This activity is awarded 1.7 ANCC pharmacotherapeutic contact hours.

    ONCOLOGY NURSING CERTIFICATION CORPORATION (ONCC)/INDIVIDUAL LEARNING NEEDS ASSESSMENT (ILNA) CERTIFICATION INFORMATION
    The program content has been reviewed by the ONCC and is acceptable for recertification points. To review certification qualifications, please visit ResearchToPractice.com/ONS2018/ILNA.

    ONCC review is only for designating content to be used for recertification points and is not for CNE accreditation. CNE programs must be formally approved for contact hours by an acceptable accreditor/approver of nursing CE to be used for recertification by ONCC. If the CNE provider fails to obtain formal approval to award contact hours by an acceptable accrediting/approval body, no information related to ONCC recertification may be used in relation to the program.

    FOR SUCCESSFUL COMPLETION
    This is a video CNE program. To receive credit, participants should read the learning objectives and faculty disclosures, watch the video, complete the Post-test with a score of 80% or better and fill out the Educational Assessment and Credit Form located at ResearchToPractice.com/ONSGI2018/CNE.

    CONTENT VALIDATION AND DISCLOSURES
    RTP is committed to providing its participants with high-quality, unbiased and state-of-the-art education. We assess conflicts of interest with faculty, planners and managers of CNE activities. Conflicts of interest are identified and resolved through a conflict of interest resolution process. In addition, all activity content is reviewed by both a member of the RTP scientific staff and an external, independent reviewer for fair balance, scientific objectivity of studies referenced and patient care recommendations.

    FACULTY — The following faculty (and their spouses/partners) reported relevant conflicts of interest, which have been resolved through a conflict of interest resolution process:

    Tanios Bekaii-Saab, MD
    Professor, Mayo Clinic College of Medicine and Science
    Co-Leader, GI Cancer Program
    Mayo Clinic Cancer Center
    Senior Associate Consultant
    Mayo Clinic
    Scottsdale, Arizona

    Consulting Agreements: Amgen Inc, ARMO BioSciences, Bayer HealthCare Pharmaceuticals, Bristol-Myers Squibb Company, Celgene Corporation, Exelixis Inc, Genentech BioOncology, Ipsen Biopharmaceuticals Inc, Merck, Roche Laboratories Inc, SillaJen; Contracted Research: Bayer HealthCare Pharmaceuticals, Boehringer Ingelheim Pharmaceuticals Inc, Boston Biomedical Pharma Inc, Bristol-Myers Squibb Company, Celgene Corporation, Lilly.

    Michael Casey, APRN-BC, FNP
    Gastrointestinal Cancer Center
    Dana-Farber Cancer Institute
    Harvard Medical School
    Boston, Massachusetts

    No relevant conflicts of interest to disclose.

    John L Marshall, MD
    Chief, Hematology and Oncology
    Director, Ruesch Center for the Cure of GI Cancers
    Lombardi Comprehensive Cancer Center
    Georgetown University
    Washington, DC

    Advisory Committee and Speakers Bureau: Amgen Inc, Bayer HealthCare Pharmaceuticals, Celgene Corporation, Genentech BioOncology, Merck.

    Jessica Mitchell, APRN, CNP, MPH
    Assistant Professor, GI Oncology
    Mayo Clinic
    Rochester, Minnesota

    No relevant conflicts of interest to disclose.

    MODERATOR — Dr Love is president and CEO of Research To Practice. Research To Practice receives funds in the form of educational grants to develop CME/CNE activities from the following commercial interests: AbbVie Inc, Acerta Pharma — A member of the AstraZeneca Group, Adaptive Biotechnologies, Agendia Inc, Agios Pharmaceuticals Inc, Amgen Inc, Ariad Pharmaceuticals Inc, Array BioPharma Inc, Astellas Pharma Global Development Inc, AstraZeneca Pharmaceuticals LP, Baxalta Inc, Bayer HealthCare Pharmaceuticals, Biodesix Inc, bioTheranostics Inc, Boehringer Ingelheim Pharmaceuticals Inc, Boston Biomedical Pharma Inc, Bristol-Myers Squibb Company, Celgene Corporation, Clovis Oncology, CTI BioPharma Corp, Dendreon Pharmaceuticals Inc, Eisai Inc, Exelixis Inc, Foundation Medicine, Genentech BioOncology, Genomic Health Inc, Gilead Sciences Inc, Halozyme Inc, ImmunoGen Inc, Incyte Corporation, Infinity Pharmaceuticals Inc, Ipsen Biopharmaceuticals Inc, Janssen Biotech Inc, administered by Janssen Scientific Affairs LLC, Jazz Pharmaceuticals Inc, Kite Pharma Inc, Lexicon Pharmaceuticals Inc, Lilly, Medivation Inc, a Pfizer Company, Merck, Merrimack Pharmaceuticals Inc, Myriad Genetic Laboratories Inc, NanoString Technologies, Natera Inc, Novartis, Novocure, Onyx Pharmaceuticals, an Amgen subsidiary, Pfizer Inc, Pharmacyclics LLC, an AbbVie Company, Prometheus Laboratories Inc, Puma Biotechnology Inc, Regeneron Pharmaceuticals Inc, Sanofi Genzyme, Seattle Genetics, Sigma-Tau Pharmaceuticals Inc, Sirtex Medical Ltd, Spectrum Pharmaceuticals Inc, Taiho Oncology Inc, Takeda Oncology, Tesaro Inc, Teva Oncology and Tokai Pharmaceuticals Inc.

    RESEARCH TO PRACTICE CME/CNE PLANNING COMMITTEE MEMBERS, STAFF AND REVIEWERS — Planners, scientific staff and independent reviewers for Research To Practice have no relevant conflicts of interest to disclose.

    This educational activity contains discussion of published and/or investigational uses of agents that are not indicated by the Food and Drug Administration. Research To Practice does not recommend the use of any agent outside of the labeled indications. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications and warnings. The opinions expressed are those of the presenters and are not to be construed as those of the publisher or grantors.

    This activity is supported by educational grants from Celgene Corporation, Eisai Inc, Exelixis Inc, Ipsen Biopharmaceuticals Inc, Merck and Taiho Oncology Inc.

    Hardware/Software Requirements:
    A high-speed Internet connection
    A monitor set to 1280 x 1024 pixels or more
    Internet Explorer 11 or later, Firefox 56 or later, Chrome 61 or later, Safari 11 or later, Opera 48 or later
    Adobe Flash Player 27 plug-in or later
    Adobe Acrobat Reader
    (Optional) Sound card and speakers for audio

    Last review date: July 2018
    Expiration date: July 2019

    There is no implied or real endorsement of any product by RTP or the American Nurses Credentialing Center.

Acknowledge and close

Watch videos
(WIFI is recommended for best performance):